Prof Peter Hillmen discusses exciting new data in CLL from EHA19

Published on

Professor Peter Hillmen from Leeds Teaching Hospital in the UK explains the latest research results presented at the 19th Congress of the European Hematology Association (EHA) on new treatments for chronic lymphocytic leukaemia (CLL). In patients with previously treated CLL, results from recent clinical trials offer great promise. Ibrutinib showed significant benefits compared to standard ofatumumab therapy. Idelalisib, combined with rituximab, continued to show significant benefits in a follow-up study. In the future, new drugs, such as ABT-199/GDC-0199, are hoped to allow short-term approaches in CLL treatment. Supported by an educational grant from Gilead Sciences Europe through Patient Empowerment Network Keywords: CLL Chronic Lymphocytic Leukaemia Prof Peter Hillmen CLL RESONATE trial Ibrutinib Idelalisib Retuximab combination of Rituximab and Idelalisib lower platelet count ABT199 MRD negative remissions Obinutuzumab Ofatumumab FCR Ibrutinib+R

View more programs featuring

Page last updated on January 26, 2016